KAHR Medical
Fusion Proteins for Treating Cancer and Autoimmune Diseases
StartupKAHR Medical is a Modi'in-Maccabim-Re'ut-based startup in the Health Tech & Life Sciences sector, established in 2005. Fusion Proteins for Treating Cancer and Autoimmune Diseases. The company has raised a total of $117.5M across 12 funding rounds, currently at the F stage. Key investors include Peregrine Ventures, aMoon Fund, Myeloma Investment Fund, among 17 total investors. The company has 11-50 employees. Core technologies: Biologicals, Cells.
With $117.5M in total funding, KAHR Medical is a F-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StageF
- ProductClinical Trial
- ModelB2B
- Employees11-50
- HQModi'in-Maccabim-Re'ut
- DistrictCenter District
- Last RoundUndisclosed
- Peregrine Ventures
- aMoon Fund
- Myeloma Investment Fund
17 investors total
15 articles covered by sources including www.prnewswire.com,
www.labiotech.eu,
www.jpost.com,
www.timesofisrael.com,
www.calcalistech.com.
What does KAHR Medical do?
KAHR is developing immuno-oncology drug candidates for the treatment of multiple types of cancer. Its lead product, DSP107, is a CD47x41BB targeting compound that simultaneously targets cancer cells, weakens their innate defenses, and activates an effective local response of both innate and adaptive immunity. KAHRs technology platform is based on multifunctional immuno-recruitment proteins (MIRP) that utilize overexpression of checkpoint antigens on cancer cells to selectively target and bind to the tumor. MIRPs bridge cancer cells to immune cells to produce a targeted synergistic effect by combining immune checkpoint inhibition with localized immune cell activation, unmasking cancer cell camouflage to enable innate immune response while recruiting the adaptive immune system to bind and selectively kill the cancer cells. In August 2020, KAHR Medical received FDA clearance to begin clinical trials on its immunotherapy drug to battle cancer.
How much funding has KAHR Medical raised?
KAHR Medical has raised $117.5M in total funding across 12 rounds. The company is currently at the F stage. Key investors include Peregrine Ventures, aMoon Fund, Myeloma Investment Fund.
What sector is KAHR Medical in?
KAHR Medical operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Cells. Target customers: Healthcare & Life Sciences, Healthcare, Patients, Life Sciences, Pharmaceuticals.
Where is KAHR Medical located?
KAHR Medical is based in Dam HaMacbim St 28, Modi'in-Maccabim-Re'ut, Israel, Center District.